Respiratory failure & ventilation
Intensive care admissions for severe immune-related adverse events associated with immune checkpoint inhibitor therapy: a 10-year cohort study
Authors' conclusion
This large ICU cohort of life-threatening irAEs reports high morbidity and mortality, particularly in patients with myositis, myocarditis, and pneumonitis. Corticosteroid refractoriness and mechanical ventilation were independently associated with ICU mortality.
Study context
- Population
- Patients admitted to the intensive care unit (ICU) for immune checkpoint inhibitor (ICI)-related immune-related adverse events (irAEs), Lille University Hospital, January 2015–May 202455 with irAE
- Participants
- 244 patients
- Outcome
- Prevalence of irAEs among ICI-treated patients admitted to the ICU
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Prevalence of irAEs among ICI-treated ICU admissions
Patients presenting an irAE
55
23%
Observational data: associations, not effects.
Further findings
Most frequent irAEs
- Myositis/myocarditis
- 29%
- Pneumonitis
- 22%
Time from first ICI infusion to irAE onset
- Median time (IQR 21-144)
- 63 days
Management
- Corticosteroids initiated
- 84%
- Corticosteroid-refractory
- 39%
- Additional immunosuppressive therapy
- 48%
- Vasopressors
- Half
- Mechanical ventilation
- 31%
ICU mortality
- ICU mortality, mostly attributable to refractory irAEs
- 33%
- Corticosteroid refractoriness: HR 12.32 (95% CI 3.26-46.52), p < 0.001
- Mechanical ventilation: HR 3.59 (95% CI 1.15-11.24), p = 0.028
- Cox proportional hazards regression; independently associated
Original publication
Intensive care admissions for severe immune-related adverse events associated with immune checkpoint inhibitor therapy: a 10-year cohort study. J Crit Care. Published 13 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →